methyl 2-methoxy-5-vinylbenzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-methoxy-5-vinylbenzoate
• 英文别名: Methyl 5-ethenyl-2-methoxybenzoate；methyl 5-ethenyl-2-methoxybenzoate
• 化学式: C₁₁H₁₂O₃
• 分子量: 192.214
• InChiKey: BDWDAQOXAPCSJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-methoxy-5-vinylbenzoate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 37.0h， 生成 5-(2-hydroxyethyl)-2-methoxybenzoic acid
  参考文献：
  名称：

  [EN] RXFP1 AGONISTS
  [FR] AGONISTES DE RXFP1

  摘要：

  The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).

  公开号：

  WO2023077040A1
• 作为产物：
  描述：

  5-甲酰基-2-甲氧基苯甲酸甲酯 、 甲基三苯基碘化膦 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 methyl 2-methoxy-5-vinylbenzoate
  参考文献：
  名称：

  钌卟啉通过钌的亚硝基中间体中间体催化烯烃的分子间氨基氧基氧化反应生成伯胺。

  摘要：

  钌卟啉催化烯烃（包括苯乙烯和1,3-二烯）的直接分子间氨基氧芳基化反应，在温和的反应条件下以中等至良好的收率得到了以O-（2,4-二硝基苯基）羟胺为伯胺的伯胺。光谱分析表明，钌-亚硝基络合物是氨基-氧化芳基化反应的关键反应中间体。

  DOI：

  10.1039/c9cc08043k

文献信息

• Hetero Diels–Alder reaction of olefin with o-quinone methides generated using (±)-binolphosphoric acid for the stereoselective synthesis of 2,4-diarylbenzopyrans: application to the formal synthesis of myristinin B/C
  作者：Santosh J. Gharpure、A. M. Sathiyanarayanan、Prasanna K. Vuram

  DOI：10.1039/c3ra43526a

  日期：——

  Hetero Diels–Alder reaction of olefin with o-quinone methides (o-QMs) generated using (±)-binolphosphoric acid was developed for the stereoselective synthesis of 2,4-diarylbenzopyrans. The method thus developed was utilized in the formal synthesis of myristinin B/C.

  开发了烯烃与使用（±）-苯酚磷酸生成的邻醌甲基化物（o- QMs）的异狄尔斯-阿尔德反应，用于立体选择性合成2,4-二芳基苯并吡喃。如此开发的方法用于形式的合成香豆素B/C。
• Photoredox Divergent 1,2-Difunctionalization of Alkenes with <i>gem</i>-Dibromides
  作者：Jian Cheng、Yixiang Cheng、Jin Xie、Chengjian Zhu

  DOI：10.1021/acs.orglett.7b03371

  日期：2017.12.1

  The redox neutral photocatalytic divergent radical 1,2-difunctionalization of a wide array of structurally varied alkenes with gem-dibromides is presented. On the basis of the electronic effect of alkenes, predictable 1,2-carboxygenation and 1,2-carbohalogenation of alkenes are readily available regardless of steric effect. This protocol affords a practical approach to the biologically important furan skeleton. It is distinguished by good regioselectivity, good functional group compatibility, and late-stage modification and thus signifies an important step forward to divergent radical difunctionalization of alkenes.
• Ruthenium porphyrin catalysed intermolecular amino-oxyarylation of alkenes to give primary amines <i>via</i> a ruthenium nitrido intermediate
  作者：Daohong Yu、Ka-Pan Shing、Yungen Liu、Haiyang Liu、Chi-Ming Che

  DOI：10.1039/c9cc08043k

  日期：——

  Ruthenium porphyrin catalysed direct intermolecular amino-oxyarylation of alkenes including styrenes and 1,3-dienes to give primary amines with O-(2,4-dinitrophenyl)hydroxylamine as the amine source was achieved in moderate to good yields under mild reaction conditions. Spectroscopic analyses revealed that a ruthenium nitrido complex was the key reaction intermediate for the amino-oxyarylation reaction

  钌卟啉催化烯烃（包括苯乙烯和1,3-二烯）的直接分子间氨基氧芳基化反应，在温和的反应条件下以中等至良好的收率得到了以O-（2,4-二硝基苯基）羟胺为伯胺的伯胺。光谱分析表明，钌-亚硝基络合物是氨基-氧化芳基化反应的关键反应中间体。
• [EN] RXFP1 AGONISTS<br/>[FR] AGONISTES DE RXFP1
  申请人：[en]BRISTOL-MYERS SQUIBB COMPANY

  公开号：WO2023077040A1

  公开（公告）日：2023-05-04

  The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).